Ceribell vs Zio

The vendor cites a 2019 Nature Medicine paper by Hannun and colleagues, a deep neural network compared with cardiologists on ambulatory ECGs, as the basis for iRhythm's algorithm. Ceribell's DECIDE study was a multicenter prospective study of rapid-response EEG (Critical Care Medicine, 2020), and the company says it has 45 peer-reviewed publications.

iRhythm sells a Zio patch service to cardiology groups: wear-and-send ECG, cloud arrhythmia detection, technician validation and a physician report, billed to payers through Medicare-enrolled IDTFs, with no public price. Its FY2025 10-K says FDA issues remain open, following a warning letter of May 25, 2023 over a Zio AT change made without clearance and a Form 483 after July 2024 inspections.

Ceribell is bought by hospital neurology services and ICUs that want bedside seizure detection, with recorders ordered under contract. A patch that goes home with a cardiac patient and a headband at an ICU bedside sit on different clinical pathways.